497 related articles for article (PubMed ID: 31200321)
21. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
[No Abstract] [Full Text] [Related]
23. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
24. Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.
Dalle S; Varey E; Nguyen JM; Dupuy A; Montaudie H; Lesage C; Mortier L; Leccia MT; Skowron F; Celerier P; Meyer N; Dutriaux C; Dalac-Rat S; Khammari A; Lebbe C; Dréno B
Eur J Dermatol; 2020 Aug; 30(4):389-396. PubMed ID: 32815816
[TBL] [Abstract][Full Text] [Related]
25. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.
Fujisawa Y; Yoshikawa S; Minagawa A; Takenouchi T; Yokota K; Uchi H; Noma N; Nakamura Y; Asai J; Kato J; Fujiwara S; Fukushima S; Uehara J; Hoashi T; Kaji T; Fujimura T; Namikawa K; Yoshioka M; Murata N; Ogata D; Matsuyama K; Hatta N; Shibayama Y; Fujiyama T; Ishikawa M; Yamada D; Kishi A; Nakamura Y; Shimiauchi T; Fujii K; Fujimoto M; Ihn H; Katoh N
J Dermatol Sci; 2019 May; 94(2):284-289. PubMed ID: 31023613
[TBL] [Abstract][Full Text] [Related]
26. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Luke JJ; Ascierto PA; Carlino MS; Gershenwald JE; Grob JJ; Hauschild A; Kirkwood JM; Long GV; Mohr P; Robert C; Ross M; Scolyer RA; Yoon CH; Poklepovic A; Rutkowski P; Anderson JR; Ahsan S; Ibrahim N; M Eggermont AM
Future Oncol; 2020 Jan; 16(3):4429-4438. PubMed ID: 31870188
[TBL] [Abstract][Full Text] [Related]
27. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
28. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.
Suciu S; Eggermont AMM; Lorigan P; Kirkwood JM; Markovic SN; Garbe C; Cameron D; Kotapati S; Chen TT; Wheatley K; Ives N; de Schaetzen G; Efendi A; Buyse M
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922786
[TBL] [Abstract][Full Text] [Related]
29. Novel adjuvant options for cutaneous melanoma.
Dimitriou F; Long GV; Menzies AM
Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
[TBL] [Abstract][Full Text] [Related]
30. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.
Kanaki T; Stang A; Gutzmer R; Zimmer L; Chorti E; Sucker A; Ugurel S; Hadaschik E; Gräger NS; Satzger I; Schadendorf D; Livingstone E
Eur J Cancer; 2019 Sep; 119():18-29. PubMed ID: 31401470
[TBL] [Abstract][Full Text] [Related]
31. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
33. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Long GV; Dummer R; Hamid O; Gajewski TF; Caglevic C; Dalle S; Arance A; Carlino MS; Grob JJ; Kim TM; Demidov L; Robert C; Larkin J; Anderson JR; Maleski J; Jones M; Diede SJ; Mitchell TC
Lancet Oncol; 2019 Aug; 20(8):1083-1097. PubMed ID: 31221619
[TBL] [Abstract][Full Text] [Related]
34. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Konto C; Hoos A; de Pril V; Gurunath RK; de Schaetzen G; Suciu S; Testori A
Lancet Oncol; 2015 May; 16(5):522-30. PubMed ID: 25840693
[TBL] [Abstract][Full Text] [Related]
36. Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma.
Ben-Porat L; Panageas KS; Hanlon C; Patel A; Halpern A; Houghton AN; Coit D
Cancer; 2006 Jan; 106(1):163-71. PubMed ID: 16331596
[TBL] [Abstract][Full Text] [Related]
37. A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden.
Isaksson K; Katsarelias D; Mikiver R; Carneiro A; Ny L; Olofsson Bagge R
Ann Surg Oncol; 2019 Sep; 26(9):2839-2845. PubMed ID: 31111349
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.
Yokota K; Takenouchi T; Fujisawa Y; Fukushima S; Uchi H; Inozume T; Kiyohara Y; Uhara H; Nakagawa K; Furukawa H; Han S; Watanabe M; Noguchi K; Yamazaki N
J Dermatol; 2024 May; 51(5):632-642. PubMed ID: 38529706
[TBL] [Abstract][Full Text] [Related]
39. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Scherrer E; Wang J; Aguiar-Ibáñez R
Clin Drug Investig; 2020 Jul; 40(7):629-643. PubMed ID: 32418051
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.
Anaya DA; Xing Y; Feng L; Huang X; Camacho LH; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Cormier JN
Cancer; 2008 May; 112(9):2030-7. PubMed ID: 18320602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
